Nimbus Therapeutics has achieved a significant preclinical milestone in collaboration with Eli Lilly and Company (Lilly), where they targeted a specific isoform of AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases.

AMPK, a key regulator of cellular energy metabolism, has long been recognized as a promising therapeutic target. Despite its potential, developing selective activators of specific AMPK isoforms has remained technically challenging, with previous attempts to effectively drug the target proving unsuccessful.

Throughout their collaboration, Nimbus has leveraged its computational approaches and structure-based drug design capabilities to help overcome these historical obstacles.

“Our team has solved a decades-old challenge in drug development with the discovery of a highly selective isoform-specific AMPK activator. This success demonstrates the power of Nimbus’ computational approach to drug discovery combined with Lilly’s deep expertise in cardiometabolic disease. I am excited by the potential of this molecule to make a meaningful difference for patients. I look forward to continuing to apply Nimbus’ discovery engine to address targets across metabolic, cardiovascular, and obesity-related diseases,” said Peter J. Tummino, PhD, President of Research and Development at Nimbus.

In October 2022, Nimbus and Lilly entered into a research collaboration and exclusive, worldwide license agreement for the development and commercialization of small molecule activators of AMPK.

Under the terms of the agreement, Nimbus is responsible for research activities and Lilly is responsible for development and commercialization efforts worldwide. Nimbus is eligible to receive research, development, and commercial milestone payments up to USD 496 million, in addition to royalties on global net sales ranging from mid-single- to low double-digits.